Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Antitumor activity and resistance mechanisms further characterized for XR-5944 and XR-11576

Nov. 21, 2002

Phase I data for NB-1011 discussed at EORTC-NCI-AACR symposium

Nov. 21, 2002

Aventis scientists present new tubulin polymerization inhibitors

Nov. 21, 2002

Phase I/II trial initiated for LE-SN-38

Nov. 20, 2002

Preclinical and early clinical data discussed for OSI-7836 in Frankfurt

Nov. 20, 2002

FDA approves SuperGen's NDA to market Mitozytrex

Nov. 20, 2002

D-63153, a new GnRH antagonist as a candidate for sex steroid-dependent diseases

Nov. 20, 2002

Bay-43-9006 scheduled to enter phase III in 2003

Nov. 20, 2002

FDA approves CMC amendment for ONYX-015

Nov. 20, 2002

Coley and GSK enter license agreement for cancer vaccines

Nov. 20, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...